Lutathera®
Pre-clinicalActive 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroenteropancreatic Neuroendocrine Tumor
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Trial Timeline
Mar 9, 2021 → Mar 31, 2026
NCT ID
NCT04727723About Lutathera®
Lutathera® is a pre-clinical stage product being developed by Novartis for Gastroenteropancreatic Neuroendocrine Tumor. The current trial status is active. This product is registered under clinical trial identifier NCT04727723. Target conditions include Gastroenteropancreatic Neuroendocrine Tumor.
What happened to similar drugs?
0 of 3 similar drugs in Gastroenteropancreatic Neuroendocrine Tumor were approved
Approved (0) Terminated (0) Active (3)
🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
3
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04727723 | Pre-clinical | Active |
Competing Products
9 competing products in Gastroenteropancreatic Neuroendocrine Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 47 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 27 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 47 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 32 |
| Lutathera + Gallium 68 Dotatate | Novartis | Phase 1 | 36 |
| Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus | Novartis | Phase 1 | 29 |
| Lanreotide Autogel 120 mg + Temozolomide (TMZ) | Ipsen | Phase 2 | 32 |
| satoreotide trizoxetan | Ipsen | Phase 1/2 | 29 |
| Lanreotide autogel | Ipsen | Phase 3 | 37 |